Coronavirus (COVID-19) Collection
Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
Several monoclonal antibodies against SARS-CoV-2 have been developed for the treatment of COVID-19 (Miguez-Rey et al., 2022). One of these is sotrovimab, which significantly reduced the risk of COVID-19 hospitalization and death due to infection with pre-Omicron SARS-CoV-2 variants in a randomized clinical trial (Gupta et al., 2021). The United States Food and Drug Administration (FDA) issued an emergency authorization to permit the use of sotrovimab for the treatment of mild-to-moderate COVID-19 in patients at high risk of progression to severe COVID-19 (US Food and Drug Administration, 2022).Monitoring the COVID-19 immune landscape in Japan
Since the COVID-19 epidemic spread on a global scale in 2020, it considerably altered daily life. With the hope of mitigating the COVID-19 risk, vaccination campaigns began in December 2020 in many countries, often using a prioritization vaccination strategy (Haas et al., 2021; Hall et al., 2021; Jentsch et al., 2021; Mathieu et al., 2021; Sasanami et al., 2022; Thompson et al., 2021). Mass vaccination campaigns occurred primarily when the original (wild-type) strain, the Alpha variant (B.1.1.7), the Beta variant (B.1.351), or other variants were dominant in circulation and against which the available vaccines provided substantial protection (Chemaitelly et al., 2021; Chung et al., 2021; Dagan et al., 2021; Haas et al., 2021; Hall et al., 2021; Pritchard et al., 2021).Stringency of containment and closures on the growth of SARS-CoV-2 in Canada prior to accelerated vaccine roll-out
Throughout 2020, non-pharmaceutical interventions (NPIs) were the primary tools employed by governments and public health agencies to slow the spread of SARS-CoV-2 (Ferguson et al. 2020, Koo et al., 2020). In Canada, as in many other countries, common NPIs included border closures, bans on non-essential travel, and mandatory physical distancing measures (McCoy et al, 2020). However, in contrast to many countries—particularly those in Europe—the authority and responsibility to implement these policies fall on provincial and territorial governments, meaning there is no formally coordinated response between them (Cameron-Blake et al., 2021).Risk factors, immune response and whole‐genome sequencing of SARS‐CoV‐2 in a cruise ship outbreak in Norway
To improve understanding of SARS-CoV-2-transmission and prevention measures on cruise ships, we investigated a Norwegian cruise ship outbreak from July to August 2020 using a multidisciplinary approach after a rapid outbreak response launched by local and national health authorities.Characteristics and Outcomes of COVID-19 in Reproductive-Aged Pregnant and Nonpregnant Women in Osaka, Japan
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan, China (Li et al., 2020, Zhou et al., 2020), and rapidly spread worldwide, imposing a major burden on healthcare systems globally. Pregnant women are considered to be at a higher risk of severe morbidity and mortality from other respiratory infections, such as influenza or SARS (Allotey et al., 2020, Blitz et al., 2020, Vintzileos et al., 2020, Xu et al., 2020), than nonpregnant women.Hypothyroidism does not lead to worse prognosis in COVID-19: findings from the Brazilian COVID-19 registry
A global health crisis was established with the emergence of COVID-19 (Gelfand et al., 2021). It is well known that individuals with some underlying medical conditions, such as cardiovascular diseases, cancer, obesity, diabetes, and hypertension, are more likely to develop severe COVID-19, require hospitalization and intensive care, and have higher mortality rates (Marcolino et al., 2021; Sanyaolu et al., 2020; Centers for Disease Control and Prevention. People with Certain Medical Conditions. September 4th, 2021).SARS-CoV-2 seroprevalence among 7950 healthcare workers in the Region of Southern Denmark
Coronavirus disease 2019 (COVID-19) surged as an ongoing worldwide pandemic throughout 2020 (Park et al., 2020; Siordia, 2020). The first Danish cases were reported in late February 2020, and the initial spread of infection most likely originated from ski tourists returning from Northern Italy and Austria (Madsen et al., 2021). The first epidemic wave in Denmark peaked in late March and early April, with 9.2 patients admitted to hospital per 100 000 population (Madsen et al., 2021; Statens Serum Institut 2021).The toll of COVID-19 on African children: A descriptive analysis on COVID-19-related morbidity and mortality among the pediatric population in Sub-Saharan Africa
Since its emergence in December 2019 in the Chinese city of Wuhan, the coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people around the world and caused over 3.9 million officially registered deaths (WHO, 2021). From the onset of this pandemic, the pathogenic aspects in the pediatric population have remained less clear, especially in Sub-Saharan Africa, where specialists' initial projections estimated a high number of cases and deaths (Cabore et al., 2020).SARS-CoV-2 seroprevalence and associated factors in Manaus, Brazil: baseline results from the DETECTCoV-19 cohort study
Infectious diseases have a profound impact on humans, particularly vulnerable populations (Fauci and Morens, 2012). The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and a lack of effective treatment and non-pharmaceutical interventions to curb transmission have led to an exponential increase in the burden of coronavirus disease 2019 (COVID-19) worldwide (Hsiang et al., 2020; Kraemer et al., 2020; Bo et al., 2021).Clinical and epidemiological characteristics of children with COVID-19 in Negeri Sembilan, Malaysia
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), remains an ongoing challenge to countries worldwide. The disease emerged in Wuhan, China in December 2019 and was declared a pandemic by the World Health Organization (WHO) on 11 March 2020 (World Health Organization, 2000). The COVID-19 outbreak in Malaysia occurred in three waves. The first wave started with three cases imported from China via Singapore on 25 January 2020 (Rahman, 2020).Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study
Chloroquine and hydroxychloroquine have been shown to be in-vitro inhibitors of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in infected Vero cells (Liu et al., 2020; Wang et al., 2020; Yao et al., 2020). This contributed to the hypothesis that such drugs could be used as prophylaxis for SARS-CoV-2 infection and for treatment of patients with coronavirus disease 2019 (COVID-19). Hydroxychloroquine is used for long-term treatment of several rheumatic diseases; it has a favourable safety profile (Ruiz-Irastorza et al., 2010; Ponticelli and Moroni, 2017) and a low cost (Ponticelli and Moroni, 2017), which is a key point when facing a pandemic.COVID-19 within a large UK prison with a high number of vulnerable adults, march to june 2020: An outbreak investigation and screening event
Coronavirus disease (COVID-19) is an infectious disease caused by the most recently discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus was unknown before the outbreak began in China in December 2019 and has since spread worldwide (Zhu et al., 2020). The impact of the epidemic has been noted in many community sectors, including institutional settings, such as prisons. Many prison residents are at higher risk of severe COVID-19 and death due to significant co-morbidities, and advanced age in some prisons (Amon, 2020; Kinner et al., 2020).Epidemiology of COVID-19 in Mexico: Symptomatic profiles and presymptomatic people
At the start of the COVID-19 pandemic, the initial reports showed that SARS-CoV-2 infection promotes pneumonia in mainly older adults, which were the group with a major risk of getting hospitalized and getting mechanical ventilation due to severe COVID-19 disease (Berumen et al., 2020; Giannouchos et al., 2020; Zheng et al., 2020). However, other age-groups had similar risks due to different factors. Moreover, with regard to control of the pandemic, asymptomatic people have attracted attention due to their ability to transmit the virus without manifesting infection symptoms, which makes them identifiable only by difficult massive tests on the general population.Undetected infectives in the Covid-19 pandemic
A critical issue in the control of an epidemic is to know the exact number of infective subjects. Current estimates of SARS-CoV-2 infection are significantly hampered by the difficulty to perform large-scale diagnostic tests, despite the current awareness that the spread of the Covid-19 pandemic is mostly caused by undetected carriers.The collective wisdom in the COVID-19 research: Comparison and synthesis of epidemiological parameter estimates in preprints and peer-reviewed articles
The outbreak of COVID-19 has posed a significant global threat. In response to the emerging infectious disease, the number of research papers has exploded in both formal publications and preprints (Wellcome Trust, 2020). Many journals used a fast track to publish COVID-19 research and made all COVID-19 work freely accessible to facilitate information sharing. In contrast to previous Zika and Ebola outbreaks, scientists were more enthusiastic about posting articles on preprint archives due to the very high transmissibility of COVID-19 (Fraser et al., 2020; Johansson et al., 2018).Early transmission of SARS-CoV-2 in South Africa: An epidemiological and phylogenetic report
PubMed, BioRxiv and MedRxiv were searched for reports on epidemiology and phylogenetic analysis using whole genome sequencing (WGS) of SARS-CoV-2. The following keywords were used: SARS-CoV-2, COVID-19, 2019-nCoV or novel coronavirus and transmission genomics, epidemiology, and phylogenetic or reproduction number. The search identified an important lack of molecular epidemiology studies in the southern hemisphere, with a few reports from Latin America and one from Africa. In other early transmission reports on SARS-CoV-2 infections in Africa, authors focused on transmission dynamics, but molecular and phylogenetic methods were missing.The role of case importation in explaining differences in early SARS-CoV-2 transmission dynamics in Canada—A mathematical modeling study of surveillance data
Both American and Canadian epidemics of coronavirus disease-2019 (COVID-19) are marked by stark geographic heterogeneities (Mishra et al., 2020). Despite reporting its first case on February 28, 2020—close to a month after Ontario on January 25th and British Columbia on January 28th—Quebec quickly became the epicenter of the Canadian COVID-19 epidemic. The disease’s mortality burden in that province, at 653 per million population, was 3.5 times as high as neighboring Ontario (186 per million) and 19 times that of British Columbia (at 35 per million) at the end of the first spring 2020 wave (Groupe de surveillance provinciale de la, 2020).Epidemiological Characteristics and Factors Associated with Critical Time Intervals of COVID-19 in Eighteen Provinces, China: A Retrospective Study
As of September 20, 2020, a total of more than 30 million confirmed cases of coronavirus disease 2019 (COVID-19), as well as more than 900,000 deaths had been reported by World Health Organization (WHO) in the worldwide (World Health Organization, 2020a; World Health Organization, 2020b). At the same time, China had reported 85,291 lab confirmed cases with 4,634 deaths (China National Health Commission of the People’s Republic of China, 2020a). Despite the WHO and international community declared and took many efforts to control this pandemic in time, our knowledge about the COVID-19 is still very limited, and the number of daily reported cases is still increasing sharply worldwide (Organization, 2020b).Human respiratory viruses, including SARS-CoV-2, circulating in the winter season 2019–2020 in Parma, Northern Italy
Viral infections of the upper and lower respiratory tracts are among the most common illnesses in humans. They occur mainly in children and infants, who can experience up to five to six episodes in any given year (Berry et al., 2015). For this reason, acute respiratory infections (ARIs) represent a persistent public health problem. Although the majority of ARIs remain confined to the upper respiratory tract (rhinosinusitis, pharyngitis, laryngitis, and tracheitis), they can cause severe manifestations when they affect the lower respiratory tract (bronchitis, bronchiolitis, and pneumonia) (Bicer et al., 2013; Tregoning and Schwarze, 2010; Zappa et al., 2008).Is Colombia an example of successful containment of the 2020 COVID-19 pandemic? A critical analysis of the epidemiological data, March to July 2020
By July 25, Colombia had confirmed 240 795 cases of COVID-19 and 8269 deaths (case fatality rate of 3.4%). All departments had reported cases, but 292 municipalities were apparently free of COVID-19 (26%) and 373 (33.2%) had seen limited transmission. Specific mortality rates by department ranged from 0 in Vichada to 1278 in Amazonas, which was 7.8 times the national rate (incidence rate ratio (IRR) = 7.8, 95% confidence interval 6.4–9.5). Using a conservative approach to assess the potential underestimation of cases, it was estimated that, by July 25, Colombia should have detected 1 328 175 cases instead of the actual 240 795 observed, an underestimation of 82%.Asymptomatic infection by SARS-CoV-2 in healthcare workers: A study in a large teaching hospital in Wuhan, China
Coronavirus Disease 2019 (COVID-19) has caused a large number of related deaths and multiple healthcare-associated outbreaks (Zhu et al., 2019; Wang et al., 2020a; Huang et al., 2020; Chen et al., 2020a). Investigators have summarised the clinical characteristics of initial onset in cases (Huang et al., 2020; Chen et al., 2020a): some had atypical clinical manifestations (e.g. severe cases only had moderate or low fever or even no fever), while some mild cases did not have pneumonia and only had low fever or mild fatigue (NHC, 2020; Guan et al., 2020).Isolation and phylogenetic analysis of SARS-CoV-2 variants collected in Russia during the COVID-19 outbreak
On March 11, 2020 the World Health Organization (WHO) characterized coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a pandemic (WHO, 2020a). The outbreak started as a cluster of pneumonia cases in late December 2019 in Wuhan, Hubei Province, China (WHO, 2020b); it has now reached the magnitude of over 12 million confirmed cases in 188 countries worldwide (Dong et al., 2020; (COVID-19 Dashboard, 2020).Epidemiological and clinical characteristics of coronavirus disease 2019 in Daegu, South Korea
The coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a new emerging coronavirus, currently named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first case of COVID-19 was reported in Wuhan, Hubei Province, China, in December 2019. Now, COVID-19 has spread to over 200 countries within only four months (Hui et al., 2020; World Health Organization, 2020a). In South Korea, the first case infected with SARS-CoV-2, a Chinese visitor from Wuhan, was reported on January 20, 2020 (Kim et al., 2020).Epidemic update of COVID-19 in Hubei Province compared with other regions in China
Since the first atypical pneumonia case, caused by a novel coronavirus was reported in Wuhan, China on December 31, 2019 (WHO, 2020a), the novel coronavirus infection outbreak quickly spread in Wuhan, the capital of Hubei Province and other districts of Hubei Province with a further spread across the Chinese mainland. By 29 Feb 2020 a total of 79,824 cases of infection had been confirmed nationwide including all administrative regions, with another 851 suspected cases. COVID-19 cases were also reported in Thailand, Japan, the Republic of Korea, Hong Kong, Taiwan, the US, and some countries in Europe (CCDCPC, 2019).Adoption of personal protective measures by ordinary citizens during the COVID-19 outbreak in Japan
The coronavirus disease 2019 (COVID-19) outbreak has become a global problem (WHO, 2020b). As of March 23, 2020, the global number of reported cases of COVID-19 totaled approximately 330,000 cases, with 14,510 deaths (WHO, 2020c). Japan reported the first case of laboratory-confirmed COVID-19 on January 15, 2020, following confirmed cases in China and Thailand (WHO, 2020d). The number of patients is increasing daily.
